(Q39873082)

English

Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels

scientific article published on 13 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels (English)

1 reference

Europe PubMed Central

15 September 2017

1 reference

based on heuristic

inferred from title

Giovanni Luca Gravina

1

1 reference

Europe PubMed Central

15 September 2017

object named as

Vincenza Dolo

5

0 references

object named as

Mauro Bologna

7

0 references

Carlo Vicentini

object named as

Carlo Vicentini

6

0 references

Danilo Millimaggi

3

object named as

Danilo Millimaggi

1 reference

Europe PubMed Central

15 September 2017

Claudio Festuccia

2

object named as

Claudio Festuccia

1 reference

Europe PubMed Central

15 September 2017

Vincenzo Tombolini

4

object named as

Vincenzo Tombolini

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

13 March 2009

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

74

1 reference

Europe PubMed Central

15 September 2017

2

1 reference

Europe PubMed Central

15 September 2017

452-457

1 reference

Europe PubMed Central

15 September 2017

Cancer biomarkers: knowing the present and predicting the future

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.01.018

7 January 2021

Identifiers

10.1016/J.UROLOGY.2009.01.018

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39873082&oldid=2091854974"